Collaboration With Zydus Cadila Expires - Karo Bio AB Continues to Develop Safer Glucocorticoids
HUDDINGE, Sweden--(BUSINESS WIRE)--Regulatory News: Karo Bio AB (publ)(STO:KARO) and the Indian pharmaceutical company Zydus Cadila have decided not to further extend their joint glucocorticoid receptor research and development program. Karo Bio focuses its continued development towards a previously not described mechanism of glucocorticoid regulation.